leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Pain Relieving Drugs Market Forecast 2017-2027

Pain Relieving Drugs Market Forecast 2017-2027

Neuropathic Pain Relieving Drugs, Narcotic Pain Relieving Drugs, Non-Narcotic Pain Relieving Drugs, Anti-Arthritic Pain Relieving Drugs, Anti-Migraine Pain Relieving Drugs

Product code: PHA0157

  • Publication date: 15/12/2016
  • Number of Pages: 306
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

The global pain relieving drugs market is expected to grow at a CAGR of 2.1% from 2021-2027. The market is expected to grow from $67.8bn in 2016 to $75.2bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 306-page report you will receive 122 tables and 121 charts – all unavailable elsewhere.

The 306 page report provides clear detailed insight into the global pain relieving drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Pain Relieving Drugs Market Forecast 2017-2027

Report Scope

Global Pain Relieving Drugs Market forecasts from 2017-2027

• Pain Relieving Drugs National Market forecasts from 2017-2027, covering:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
- Brazil
- China
- Russia
- India
- Rest of the World

• Global Pain Relieving Drugs submarkets and their leading drugs forecasts from 2017-2027 covering:
- Narcotic Pain Relieving Drugs
- Non-Narcotic Pain Relieving Drugs
- Neuropathic Pain Relieving Drugs
- Anti-Migraine Pain Relieving Drugs
- Anti-Arthritic Pain Relieving Drugs

• Analysis of the key factors driving and restraining the growth of the pain relieving drugs market from 2017-2027

Visiongain’s study is intended for anyone requiring commercial analyses for the pain relieving drugs market. You find data, trends and predictions.

Buy our report today Pain Relieving Drugs Market Forecast 2017-2027: Neuropathic Pain Relieving Drugs, Narcotic Pain Relieving Drugs, Non-Narcotic Pain Relieving Drugs, Anti-Arthritic Pain Relieving Drugs, Anti-Migraine Pain Relieving Drugs.

visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1. Report Overview
1.1 Global Pain Relieving Drugs: Market Overview
1.2 Global Pain Relieving Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction to Pain and Pain Management
2.1 Pain: A Sensory and Emotional Phenomenon
2.1.1 Pain: A Short History
2.1.2 Pain Pathways and the Origin of Pain
2.2 The World Health Organisation (WHO) Pain Ladder
2.2.1 Classification of Pain
2.2.1.1 Acute Pain
2.2.1.2 Chronic Pain
2.3 The Psychosocial Effects of Chronic Pain
2.3.1 Chronic Cancer Pain
2.3.2 Neuropathic Pain
2.3.3 Identifying Neuropathic Pain
2.4 The Neurochemistry of Pain
2.4.1 Prostaglandins
2.4.2 Opioids
2.5 Pain Management – A Brief Overview
2.6 Pain Management Drugs
2.6.1 The Use of Opioids in Pain Treatment
2.6.2 OTC Pain Relievers
2.7 Market Definition

3. World Pain Relieving Drugs Market 2017-2027
3.1 Global Pain Relieving Drugs: Market Overview
3.1.1 Categorisation of the Global Pain Relieving Drug Market
3.1.2 Pain Relieving Drugs: A Growing Market
3.2 The Global Pain Relieving Drugs Market in 2016
3.2.1 Market Dominance of Arthritic Pain Relieving Drugs
3.3 Global Pain Relieving Drugs: Market Forecast 2017-2027
3.3.1 Market Sectors That Will Drive Growth
3.3.2 Abuse Deterrents and Safety Measures Will Boost Narcotic Pain Relieving Drugs Market Growth
3.3.3 Changing Market Shares by Sector 2016-2027

4. Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2017-2027
4.1 The Global Narcotic Pain Relieving Drugs Market in 2016
4.1.1 Global Narcotic Pain Relieving Drugs: Market Forecast 2016-2027
4.1.2 Changing Market Shares By Leading Drugs 2016-2027
4.2 Opana ER (Endo Pharmaceuticals): Market Analysis
4.2.1 Tamper-Proof Opana ER Products
4.2.2 Opana ER: Historical Sales Analysis, 2014-2016
4.2.3 Opana ER: Sales Forecast 2016-2027
4.3 Duragesic: Market Analysis
4.3.1 Duragesic: Historical Sales Analysis, 2014-2016
4.3.2 Duragesic: Sales Forecast 2016-2027
4.4 Oxycontin ER: Market Analysis
4.4.1 Tamper Resistant Oxycontin ER
4.4.2 Oxycontin ER: Patent Expiries and Legal Battles
4.4.3 Oxycontin ER: Sales Forecast 2016-2027
4.5 Ultram: Market Analysis
4.5.1 Ultram: Sales Forecast 2016-2027
4.6 Zaldiar/Ixprim: Market Analysis
4.6.1 Zaldiar/Ixprim: Historical Sales Analysis, 2014-2016
4.6.2 Zaldiar/Ixprim: Sales Forecast 2016-2027
4.7 Other Narcotic Pain Relieving Drugs
4.7.1 Subsys (Insys Therapeutics)
4.7.2 Oxecta (Pfizer)
4.7.3 Other Narcotic Pain Relieving Drugs: Sales Forecast 2016-2027

5. Non-Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2017-2027
5.1 The Global Non-Narcotic Pain Relieving Drugs Market in 2016
5.1.1 Global Non-Narcotic Pain Relieving Drugs: Market Forecast 2016-2027
5.1.2 Changing Market Shares by Leading Drugs 2016-2027
5.2 Aspirin (Bayer): Market Analysis
5.2.1 Aspirin (Bayer): Historical Sales Analysis, 2014-2016
5.2.2 Aspirin (Bayer): Sales Forecast 2016-2027
5.3 Panadol: Market Analysis
5.3.1 Panadol: Historical Sales Analysis, 2014-2016
5.3.2 Panadol: Sales Forecast 2016-2027
5.4 Advil: Market Analysis
5.4.1 Advil: Historical Sales Analysis, 2014-2016
5.4.2 Advil: Sales Forecast 2016-2027
5.5 Tylenol: Market Analysis
5.5.1 Tylenol: Sales Forecast 2016-2027
5.6 Other Non-Narcotic Pain Drugs
5.6.1 Exparel (Pacira Pharmaceuticals)
5.6.2 Other Non-Narcotic Pain Drugs: Sales Forecast 2016-2027

6. Neuropathic Pain Relieving Drugs: World Market Analysis and Forecast, 2017-2027
6.1 An Introduction to Neuropathic Pain
6.1.1 Identifying Neuropathic Pain
6.1.2 Pharmacological Interventions for Neuropathic Pain
6.1.2.1 Analgesics in Neuropathic Pain
6.1.2.2 Anti-Convulsants
6.1.2.3 Local Anaesthetics
6.1.2.4 Anti-Depressants
6.1.2.5 Aldose Reductase Inhibitors
6.1.3 The Global Neuropathic Pain Relieving Drugs Market in 2016
6.1.4 Global Neuropathic Pain Relieving Drugs: Market Forecast 2016-2027
6.1.5 Changing Market Shares by Leading Drugs 2016-2027
6.2 Lidoderm: Market Analysis
6.2.1 Lidoderm Patent Expiry and Endo Pharma – Watson/Actavis Agreement
6.2.2 Lidoderm Marketing Probe
6.2.3 Lidoderm: Historical Sales Analysis, 2014-2016
6.2.4 Lidoderm: Sales Forecast 2016-2027
6.3 Lyrica: Market Analysis
6.3.1 Lyrica: Historical Sales Analysis, 2014-2016
6.3.2 Lyrica: Sales Forecast 2016-2027
6.4 Cymbalta: Market Analysis
6.4.1 Cymbalta: Historical Sales Analysis, 2014-2016
6.4.2 Cymbalta: Sales Forecast 2016-2027
6.5 Neurontin: Market Analysis
6.5.1 Neurontin: Historical Sales Analysis, 2014-2016
6.5.2 Neurontin: Sales Forecast 2016-2027
6.6 Nucynta: Market Analysis
6.6.1 Nucynta: Historical Sales Analysis, 2014-2016
6.6.2 Nucynta: Sales Forecast 2016-2027
6.7 Other Neuropathic Pain Relieving Drugs
6.7.1 Retigabine (GSK; Valeant)
6.7.2 Other Neuropathic Pain Relieving Drugs: Sales Forecast 2016-2027

7. Anti-Migraine Drugs: World Market Analysis and Forecast, 2017-2027
7.1 Migraine: An Introduction
7.1.1 Management of Migraine
7.1.2 Drugs Being Used in the Treatment of Migraine
7.1.3 Other Migraine Relieving Techniques
7.1.4 The Global Anti-Migraine Pain Relieving Drugs Market in 2016
7.1.5 Global Anti-Migraine Pain Relieving Drugs: Market Forecast 2016-2027
7.1.6 Changing Market Shares by Leading Drugs 2016-2027
7.2 Relpax: Market Analysis
7.2.1 Relpax: Historical Sales Analysis, 2014-2016
7.2.2 Relpax: Sales Forecast 2016-2027
7.3 Maxalt: Market Analysis
7.3.1 Maxalt: Historical Sales Analysis, 2014-2016
7.3.2 Maxalt: Sales Forecast 2016-2027
7.4 Imitrex/Imigran: Market Analysis
7.4.1 Imitrex/Imigran: Historical Sales Analysis, 2014-2016
7.4.2 Imitrex/Imigran: Sales Forecast 2016-2027
7.5 Zomig: Market Analysis
7.5.1 Zomig: Licensing Transfers and Exclusivity
7.5.2 Zomig: Historical Sales Analysis, 2014-2016
7.5.3 Zomig: Sales Forecast 2016-2027
7.6 Botox (Allergan): Market Analysis
7.6.1 Botox: Historical Sales Analysis, 2014-2016
7.6.2 Botox: Sales Forecast 2016-2027
7.7 Treximet: Market Analysis
7.7.1 Treximet: Agreements Between GSK, Pozen Pharmaceuticals and Pernix Therapeutics
7.7.2 The Generic Treats to Treximet
7.7.3 Treximet: Historical Sales Analysis, 2014-2016
7.7.4 Treximet: Sales Forecast 2016-2027
7.8 Axert: Market Analysis
7.8.1 Axert: Historical Sales Analysis, 2014-2016
7.8.2 Axert: Sales Forecast 2016-2027
7.9 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast, 2016-2027
7.10 Anti-Migraine Pain Relieving Drugs Market – Future Prospects
7.10.1 Unmet Needs in the Treatment of Migraine

8. Anti-Arthritic Pain Drugs: World Market Analysis and Forecast, 2017-2027
8.1 Understanding Arthritis: An Introduction to its Aetiology and Prevalence
8.1.1 Management of Arthritic Conditions
8.1.2 Drugs Being Used In the Treatment Of Arthritis
8.1.2.1 Analgesics as Pain Relieving Drugs
8.1.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
8.1.2.3 Corticosteroids
8.1.2.4 Disease Modifying Anti-Rheumatic Drugs (DMARDS)
8.1.3 Biological Drugs in the Treatment of Arthritis
8.1.3.1 Biologics Used for Rheumatoid Arthritis
8.1.3.2 The Potential Side Effects of Biologics in the Treatment of Arthritis
8.1.4 The Global Anti-Arthritis Pain Relieving Drugs Market in 2016
8.1.5 Global Anti-Arthritis Pain Relieving Drugs: Market Forecast 2016-2027
8.1.6 Changing Market Shares by Leading Drugs, 2016-2027
8.2 Humira: Market Analysis
8.2.1 Humira: Historical Sales Analysis, 2014-2016
8.2.2 Humira: Sales Forecast 2016-2027
8.3 Enbrel: Market Analysis
8.3.1 Enbrel: Co-Promotions and Marketing Rights
8.3.2 Enbrel: Historical Sales Analysis, 2014-2016
8.3.3 Enbrel: Patent Expiries and Potential Competition, 2016-2027
8.3.4 Enbrel: Sales Forecast 2016-2027
8.4 Remicade: Market Analysis
8.4.1 Remicade: Historical Sales Analysis, 2014-2016
8.4.2 Remicade: Patent Expiries and Potential Competition, 2016-2027
8.4.3 Remicade: Sales Forecast 2016-2027
8.5 Voltaren: Market Analysis
8.5.1 Voltaren: Historical Sales Analysis, 2014-2016
8.5.2 Voltaren: Sales Forecast 2016-2027
8.6 Rituxan (Rituximab, MabThera): Market Analysis
8.6.1 Rituxan: Historical Sales Analysis, 2014-2016
8.6.2 Rituxan: Patent Expiries and Potential Competition, 2016-2027
8.6.3 Rituxan: Sales Forecast 2016-2027
8.7 Celebrex: Market Analysis
8.7.1 Celebrex: Historical Sales Analysis, 2014-2016
8.7.2 Celebrex: Patents, Exclusivity, and Competition, 2016-2027
8.7.3 Celebrex: Sales Forecast 2016-2027
8.8 Arcoxia: Market Analysis
8.8.1 Arcoxia: Historical Sales Analysis, 2014-2016
8.8.2 Arcoxia: Sales Forecast 2016-2027
8.9 Other Anti-Arthritis Pain Relieving Drugs
8.9.1 Duexa (Horizon Pharma)
8.9.2 Lodotra/RAYOS (Horizon Pharma; Skyepharma)
8.9.3 Ofatumumab (Genmab, GSK)
8.9.4 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast 2016-2026
8.10 Anti-Arthritic Pain Relieving Drug Market – Future Prospects

9. Leading National Markets for Pain Relieving Drugs, 2017-2027
9.1 The Pain Relieving Drug Market by Region
9.1.1 The Global Distribution of Pain Relieving Drugs In 2016
9.2 Leading National Markets: Forecast, 2016-2027
9.2.1 Changing Market Shares by Region, 2016-2027
9.3 Regional Pain Relieving Drugs Markets: Analysis and Forecasts, 2016-2027
9.4 United States: The Largest Pain Relieving Drug Market
9.5 The EU5 Markets
9.5.1 EU5 Markets: Changing Market Shares by Country, 2016-2027
9.5.2 Germany
9.5.3 UK
9.5.4 France
9.5.5 Italy
9.5.6 Spain
9.6 Japan
9.7 China
9.8 Brazil
9.9 India
9.10 Russia
9.11 Rest of the World

10. Pain Relieving Drugs: R&D Pipeline 2017-2027
10.1 Innovative Products Currently In Development Will Drive Growth
10.1.1 Large Developmental Pipelines Encouraged By High Potential Growth
10.2 Development Pipeline for Narcotic Pain Relieving Drugs
10.2.1 Remoxy (Durect, Pain Therapeutics, Pfizer)
10.2.2 MoxDuo IR (Shire; China Aoxing; QRxPharma)
10.2.3 ALO-02 (Pfizer)
10.2.4 DETERx - COL-003 (Collegium Pharmaceuticals)
10.2.5 Acurox (Acura; Pfizer)
10.2.6 Morphine-6-Glucuronide (Paion)
10.2.7 Acuracet (Acura)
10.2.8 ARX-02 (AcelRx Pharmaceuticals)
10.2.9 Zohydro ER (Zogenix)
10.2.10 BEMA Buprenorphine (BioDelivery Sciences; Endo Pharmaceuticals)
10.2.11 Rapidly Acting Topical Analgesic (Vapogenix Inc)
10.2.12 VB100 (Vitality Biopharma Inc)
10.2.13 VB210 (Vitality Biopharma Inc)
10.3 Development Pipeline for Non-Narcotic Pain Relieving Drug
10.3.1 Lofexidine Hydrochloride (US World Meds)
10.3.2 Synera (Nuvo Research)
10.3.3 Neosaxitoxin (Proteus SA; Boston Children Hospital)
10.3.4 OMS103 (Omeros)
10.3.5 Tetrodotoxin (CK Life Sciences; WEX Pharmaceuticals)
10.4 Development Pipeline for Neuropathic Pain Relieving Drugs
10.4.1 Perampanel (Eisai)
10.4.2 Serenbotase (Syntaxin, Ipsen, Allergan)
10.4.3 EMA401 (Spinifex Pharmaceuticals)
10.4.4 Ralfinamide (Newron)
10.4.5 NT-11624 (Neurotune)
10.4.6 AmiKet (Immune Pharmaceuticals)
10.4.7 Eladur (Durect; Impax Laboratories)
10.4.8 Clonidine Gel (Arcion Therapeutics; BioDelivery Sciences)
10.4.9 AVP-923 (Avanir Pharmaceuticals)
10.4.10 ARC-2022 (Arcion Therapeutics)
10.4.11 TV-45070 Topical (Teva Pharmaceuticals)
10.4.12 LX9211 (Lexicon Pharmaceuticals)
10.5 Development Pipeline for Anti-Migraine Pain Relieving Drugs
10.5.1 Zecuity (NuPathe; Teva)
10.5.2 Lasmiditan (CoLucid Pharmaceuticals)
10.5.3 NXN-188 (NeurAxon)
10.5.4 Levadex/Semprana (Allergan)
10.5.5 ALD403(Alder Biopharmaceuticals Inc)
10.6 Development Pipeline for Anti-Arthritis Pain Relieving Drugs
10.6.1 Zavryl/Ibuprofen-PC (PLx Pharma)
10.6.2 Naproxcinod (NicOx)
10.6.3 Xeljanz (Pfizer)
10.6.4 Masitinib (AB Science)
10.6.5 Belimumab (GSK, Human Genome Sciences)
10.6.6 Fasinumab (Teva Pharmaceuticals)
10.7 What Does the Future Hold for Pain Relieving Drugs Research and Development?
10.8 Solubility: A Hindrance to Drug Development
10.9 Monoclonal Antibodies (MAbs) – Potential Novel Pain Drugs Facing Challenges
10.10 New Opioids Providing Opportunities for Growth
10.11 The Potential Use of Cannabinoids In Pain Relief

11. Qualitative Analysis for the Global Pain Relieving Drugs Market, 2017-2027
11.1 Market Factors Influencing the Pain Relieving Drugs Market
11.2 SWOT Analysis of the Pain Relieving Drugs Market, 2016-2027
11.2.1 Strengths
11.2.1.1 Cost Effectiveness: A Major Driver for Growth
11.2.1.2 Promising Candidates in the R&D Pipeline
11.2.2 Weaknesses
11.2.2.1 Product Withdrawals and Slow Regulatory Approvals
11.2.2.2 Concerns Over Drug Side Effects
11.2.2.3 Education in Pain Management is a Key Unmet Need
11.2.3 Opportunities
11.2.3.1 Reformulations of Existing Drugs Will Drive Market Growth
11.2.3.2 Reforms in Narcotics Offer Growth Opportunities
11.2.3.3 Ageing Population – Growth Driver for Pain Relieving Drugs
11.2.3.4 The Economic Benefits of Expansion Into Emerging Markets
11.2.3.5 OTC Switching May Help To Delay Generic Erosion
11.2.4 Threats
11.2.4.1 Patent Expiries Will Lead to Generic Competition
11.2.4.2 Regulatory and Pricing Scrutiny Could Suffocate Market Growth
11.2.4.3 Inadequate Reimbursement Levels: A Potential Restraint On Market Growth
11.3 STEP Analysis of the Pain Relieving Drugs Market, 2016-2027
11.3.1 Social Factors Affecting the Pain Relieving Drugs Market
11.3.2 Technological Factors Affecting the Pain Relieving Drugs Market
11.3.3 Economic Factors Affecting the Pain Relieving Drugs Market
11.3.4 Political Factors Affecting the Pain Relieving Drugs Market

12. Conclusions
12.1 Market Overview
12.2 The Likely Impacts of Patent and Exclusivity Expiries on Pain Relieving Drugs
12.3 Major Growth Drivers for Pain Relieving Drugs
12.4 Under-Served Needs in Neuropathic Pain Leaves Room for Growth
12.5 The Narcotic Pain Relieving Drugs Market: Its Driving and Restraining Factors
12.6 Botox Approval Expected to Boost Anti-Migraine Submarket
12.7 The Rise of Biological Anti-Arthritic Pain Drugs
12.8 Emerging Markets Set To Drive Steer Market Forward
12.9 What Does The Future Hold For Pain Relieving Drugs?

Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Figures
Figure 1.1 Global Pain Relieving Drugs Market: Submarkets, 2017
Figure 2.1 Categories of Pain
Figure 3.1 The Global Pain Relieving Drugs Market: Revenue ($bn) by Sector, 2016
Figure 3.2 The Global Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 3.3 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2016-2021
Figure 3.4 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2021-2027
Figure 3.5 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2016-2027
Figure 3.6 The Global Pain Relieving Drugs Market: Revenue ($bn) by Sector, 2016
Figure 3.7 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2016
Figure 3.7 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2021
Figure 3.8 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2027
Figure 4.1 The Global Narcotic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016
Figure 4.2 The Global Narcotic Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 4.3 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016
Figure 4.4 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2021
Figure 4.5 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2027
Figure 4.6 Opana ER: Historical Sales ($bn, AGR%), 2014-2016
Figure 4.7 Opana ER: Sales Forecast ($bn, AGR%), 2016-2027
Figure 4.8 Duragesic: Historical Sales ($bn, AGR%), 2014-2016
Figure 4.9 Duragesic: Sales Forecast ($bn, AGR%), 2016-2027
Figure 4.10 Oxycontin: Sales Forecast ($bn, AGR%), 2016-2027
Figure 4.11 Ultram: Sales Forecast ($bn, AGR%), 2016-2027
Figure 4.12 Zaldiar/Ixprim: Historical Sales ($bn, AGR%), 2014-2016
Figure 4.13 Zaldiar/Ixprim: Sales Forecast ($bn, AGR%), 2016-2027
Figure 4.14 Other Narcotic Pain Relieving Drugs: Sales Forecast ($bn, AGR%), 2016-2027
Figure 5.1 The Global Non-Narcotic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016
Figure 5.2 The Global Non-Narcotic Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 5.3 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016
Figure 5.4 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2021
Figure 5.5 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2027
Figure 5.6 Aspirin and Aspirin Cardio: Historical Sales ($bn, AGR%), 2014-2016
Figure 5.7 Aspirin (Bayer): Sales Forecast ($bn, AGR%), 2016-2027
Figure 5.8 Panadol (GSK): Historical Sales ($bn, AGR%), 2014-2016
Figure 5.9 Panadol (GSK): Sales Forecast ($bn, AGR%), 2016-2027
Figure 5.10 Advil: Sales Forecast ($bn, AGR%), 2016-2027
Figure 5.11 Tylenol: Sales Forecast ($bn, AGR%), 2016-2027
Figure 5.12 Other Non-Narcotic Pain Drugs: Sales Forecast ($bn, AGR%), 2016-2027
Figure 6.1 The Global Neuropathic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016
Figure 6.2 The Global Neuropathic Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 6.3 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016
Figure 6.4 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2021
Figure 6.5 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2027
Figure 6.6 Lidoderm: Historical Sales ($bn, AGR%), 2014-2016
Figure 6.7 Lidoderm: Sales Forecast ($bn, AGR%), 2016-2027
Figure 6.8 Lyrica: Historical Sales ($bn, AGR%), 2014-2016
Figure 6.9 Lyrica: Sales Forecast ($bn, AGR%), 2016-2027
Figure 6.10 Cymbalta: Historical Sales ($bn, AGR%), 2014-2016
Figure 6.11 Cymbalta: Sales Forecast ($bn, AGR%), 2016-2027
Figure 6.12 Neurontin: Historical Sales ($bn, AGR%), 2014-2017
Figure 6.13 Neurontin: Sales Forecast ($bn, AGR%), 2016-2027
Figure 6.14 Nucynta: Historical Sales ($bn, AGR%), 2014-2016
Figure 6.15 Nucynta: Sales Forecast ($bn, AGR%), 2016-2027
Figure 6.16 Other Neuropathic Pain Relieving Drugs: Sales Forecast ($bn, AGR%), 2016-2027
Figure 7.1 The Global Anti-Migraine Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016
Figure 7.2 The Global Anti-Migraine Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 7.3 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016
Figure 7.4 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2021
Figure 7.5 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2027
Figure 7.6 Relpax: Historical Sales ($bn, AGR%), 2014-2016
Figure 7.7 Relpax: Sales Forecast ($bn, AGR%), 2016-2027
Figure 7.8 Maxalt: Historical Sales ($m, AGR%), 2014-2016
Figure 7.9 Maxalt: Sales Forecast ($bn, AGR%), 2016-2027
Figure 7.10 Imitrex/Imigran: Historical Sales ($bn, AGR%), 2014-2016
Figure 7.11 Imitrex/Imigran: Sales Forecast ($bn, AGR%), 2016-2027
Figure 7.12 Zomig: Historical Sales ($bn, AGR%), 2014-2016
Figure 7.13 Zomig: Sales Forecast ($bn, AGR%), 2016-2027
Figure 7.14 Botox (Allergan): Historical Sales ($bn, AGR%), 2014-2016
Figure 7.15 Botox: Sales Forecast ($bn, AGR%), 2016-2027
Figure 7.16 Treximet: Historical Sales ($bn, AGR%), 2014-2016
Figure 7.17 Treximet: Sales Forecast ($bn, AGR%), 2016-2027
Figure 7.18 Axert: Historical Sales ($bn, AGR%), 2014-2016
Figure 7.19 Axert: Sales Forecast ($bn, AGR%), 2016-2027
Figure 7.20 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast ($bn, AGR%), 2016-2027
Figure 8.1 The Global Anti-Arthritic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016
Figure 8.2 The Global Anti-Arthritis Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 8.3 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016
Figure 8.4 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2021
Figure 8.5 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by leading Drugs, 2027
Figure 8.6 Humira: Historical Sales ($bn), 2014-2016
Figure 8.7 Humira: Sales Forecast ($bn, AGR%), 2016-2027
Figure 8.8 Enbrel: Historical Sales ($bn, AGR%), 2014-2016
Figure 8.9 Enbrel: Sales Forecast ($bn, AGR%), 2016-2027
Figure 8.10 Remicade: Historical Sales ($bn) by Company, 2014-2016
Figure 8.11 Remicade: Sales Forecast ($bn, AGR%), 2016-2027
Figure 8.12 Voltaren: Historical Sales ($bn, AGR %), 2014-2016
Figure 8.14 Rituxan: Historical Sales ($bn), 2014-2016
Figure 8.15 Rituxan: Sales Forecast ($bn, AGR%), 2016-2027
Figure 8.16 Celebrex: Historical Sales ($bn), 2014-2016
Figure 8.17 Celebrex: Sales Forecast ($bn, AGR%), 2016-2027
Figure 8.18 Arcoxia: Historical Sales ($bn), 2014-2016
Figure 8.19 Arcoxia: Sales Forecast ($bn, AGR%), 2016-2027
Figure 8.20 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast ($bn, AGR%), 2016-2027
Figure 9.1 The Global Pain Relieving Drugs Market: Market Size ($bn) by Region, 2016
Figure 9.2 US, EU5, China, and Japan Pain Relieving Drugs Market: Market Forecast ($bn), 2016-2027
Figure 9.3 Russia, Brazil, India, and Rest of World Pain Relieving Drugs Markets: Market Forecasts ($bn), 2016-2027
Figure 9.4 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2016-2021
Figure 9.5 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2021-2027
Figure 9.6 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2016-2027
Figure 9.7 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2016
Figure 9.8 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2021
Figure 9.9 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2027
Figure 9.10 US Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 9.11 The EU5 Pain Relieving Drugs Market: Revenues ($bn) by Country, 2016
Figure 9.12 Germany, France, UK, Italy, and Spain Pain Relieving Drugs Market: Market Forecast ($bn), 2016-2027
Figure 9.13 The EU5 Pain Relieving Drugs Market: Market Shares (%) by Country, 2016
Figure 9.14 The EU5 Pain Relieving Drugs Market: Market Shares (%) by Country, 2021
Figure 9.15 The EU5 Pain Relieving Drugs Market: Market Shares (%) by Country, 2027
Figure 9.16 German Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 9.17 The UK Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 9.18 French Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 9.19 Italian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 9.20 Spanish Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 9.21 Japanese Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 9.22 Chinese Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 9.23 Brazilian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 9.24 Indian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 9.25 Russian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 9.26 Rest of the World Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
Figure 11.1 Global Population Forecast: Total Population (m) and Over-65 Population (m), 2016, 2021, 2027, 2030
Figure 12.1 Pain Relieving Drugs: Market Forecast ($bn)
Figure 12.2 Pain Relieving Drugs: Market Forecast ($bn) by Sector, 2016-2027

List of Tables
Table 1.1 (Sample) Global Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Region, 2016-2027
Table 2.1 Comparison of Acute and Chronic Pain
Table 2.2 Therapeutic Classes In Pain Management
Table 3.1 The Global Pain Relieving Drugs Market: Revenue ($bn) and Market Shares (%) by Sector, 2016
Table 3.2 The Global Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Sector, 2016-2027
Table 3.3 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2016-2021, 2021-2027, 2016-2027
Table 3.4 The Global Pain Relieving Drugs Market: Revenue ($bn) by Sector, 2016, 2021, 2027
Table 3.5 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2016, 2021, 2027
Table 4.1 The Global Narcotic Pain Relieving Drugs Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2016
Table 4.2 The Global Narcotic Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2016-2027
Table 4.3 The Narcotic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016, 2021, 2027
Table 4.4 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
Table 4.5 Opana ER: Historical Sales ($bn, AGR%), 2014-2016
Table 4.6 Opana ER: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 4.7 Duragesic: Historical Sales ($bn, AGR%), 2014-2016
Table 4.8 Duragesic: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 4.9 Oxycontin: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 4.10 Ultram: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 4.11 Zaldiar/Ixprim: Historical Sales ($bn, AGR%), 2014-2016
Table 4.12 Zaldiar/Ixprim: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 4.13 Other Narcotic Pain Relieving Drugs: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 5.1 The Global Non-Narcotic Pain Relieving Drugs Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2016
Table 5.2 The Global Non-Narcotic Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2016-2027
Table 5.3 The Non-Narcotic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016, 2021, 2027
Table 5.4 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
Table 5.5 Aspirin and Aspirin Cardio: Historical Sales ($bn, AGR%), 2014-2016
Table 5.6 Aspirin (Bayer): Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 5.7 Selected Panadol Formulations
Table 5.8 Panadol (GSK): Historical Sales ($bn, AGR%), 2014-2016
Table 5.9 Panadol (GSK): Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 5.10 Selected Advil Products and Product Details
Table 5.11 Advil: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 5.12 Selected Tylenol Products and Product Details
Table 5.13 Tylenol: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 5.14 Other Non-Narcotic Pain Drugs: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 6.1 Key Drug Indications for Neuropathic Pain
Table 6.2 Key FDA-Approved Drugs Indicated for Neuropathic Pain
Table 6.3 The Global Neuropathic Pain Relieving Drugs Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2016
Table 6.4 The Global Neuropathic Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2016-2027
Table 6.5 The Neuropathic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016, 2021, 2027
Table 6.6 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
Table 6.7 Lidoderm: Historical Sales ($bn, AGR%), 2014-2016
Table 6.8 Lidoderm: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 6.9 Lyrica: Historical Sales ($bn, AGR%), 2014-2017
Table 6.10 Lyrica: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 6.11 Cymbalta: Historical Sales ($bn, AGR%), 2014-2016
Table 6.12 Cymbalta: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 6.13 Neurontin: Historical Sales ($bn, AGR%), 2014-2016
Table 6.14 Neurontin: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 6.15 Nucynta: Historical Sales ($bn, AGR%), 2014-2016
Table 6.16 Nucynta: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 6.17 Other Neuropathic Pain Relieving Drugs: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 7.1 The Global Anti-Migraine Pain Relieving Drugs Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2016
Table 7.2 The Global Anti-Migraine Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 7.3 The Anti-Migraine Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016, 2021, 2027
Table 7.4 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
Table 7.5 Relpax: Historical Sales ($bn, AGR%), 2014-2016
Table 7.6 Relpax: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 7.7 Maxalt: Historical Sales ($bn, AGR%), 2014-2016
Table 7.8 Maxalt: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 7.9 Imitrex/Imigran: Historical Sales ($bn, AGR%), 2008-2013
Table 7.10 Imitrex/Imigran: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 7.11 Zomig: Historical Sales ($bn, AGR%), 2014-2016
Table 7.12 Zomig: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 7.13 Botox (Allergan): Historical Sales ($bn, AGR%), 2014-2016
Table 7.14 Botox: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 7.15 Treximet: Historical Sales ($bn, AGR%), 2014-2016
Table 7.16 Treximet: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 7.17 Axert: Historical Sales ($bn, AGR%), 2014-2016
Table 7.18 Axert: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 7.19 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 8.1 Selected Examples of Anti-Arthritic Pain Relieving Drugs
Table 8.2 The Global Anti-Arthritic Pain Relieving Drugs Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2016
Table 8.3 The Global Anti-Arthritis Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2016-2027
Table 8.4 The Anti-Arthritis Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016, 2021, 2027
Table 8.5 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
Table 8.6 Humira: Historical Sales ($bn, AGR%), 2014-2016
Table 8.7 Humira: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 8.8 Enbrel: Historical Sales ($bn, AGR%, 2014-2016
Table 8.9 Enbrel: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 8.10 Remicade: Historical Sales ($bn, AGR%) by Company, 2014-2016
Table 8.11 Remicade: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 8.12 Voltaren: Historical Sales ($bn, AGR%), 2014-2016
Table 8.13 Voltaren: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 8.14 Rituxan: Historical Sales ($bn, AGR%), 2014-2016
Table 8.15 Rituxan: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 8.16 Celebrex: Historical Sales ($bn, AGR%), 2014-2016
Table 8.17 Celebrex: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 8.18 Arcoxia: Historical Sales ($bn, AGR%), 2014-2016
Table 8.19 Arcoxia: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 8.20 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 9.1 The Global Pain Relieving Drugs Market: Market Size ($bn) and Market Share (%) by Region, 2016
Table 9.2 Global Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Region, 2016-2027
Table 9.3 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2016-2021, 2021-2027, and 2016-2027
Table 9.4 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2016, 2021, 2027
Table 9.5 US Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 9.6 The EU5 Pain Relieving Drugs Market: Revenue ($bn) and Market Share (%) by Country, 2013
Table 9.7 EU5 Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 9.8 The EU5 Pain Relieving Drugs Market: Market Share (%) by Country, 2016, 2021, 2027
Table 9.9 The German Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 9.10 The UK Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2026
Table 9.11 French Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 9.12 Italian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 9.13 Spanish Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 9.14 Japanese Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 9.15 Chinese Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 9.16 Brazilian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 9.17 Indian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 9.18 Russian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 9.19 Rest of the World Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
Table 10.1 R&D Pipeline for Narcotic Pain Relieving Drugs
Table 10.2 R&D Pipeline for Non-Narcotic Pain Relieving Drugs
Table 10.3 R&D Pipeline for Neuropathic Pain Relieving Drugs
Table 10.4 R&D Pipeline for Anti-Migraine Pain Relieving Drugs
Table 10.5 R&D Pipeline for Anti-Arthritis Pain Relieving Drugs
Table 11.1 Pain Relieving Drugs: Market Drivers and Restraints 2016-2027
Table 11.2 SWOT Analysis of the Pain Relieving Drugs Market, 2016-2027
Table 11.3 Global Population Forecast: Total Population (m) and Over-65 Population (m, %), 2016, 2021, 2027, 2030
Table 11.4 STEP Analysis of the Pain Relieving Drugs Market, 2016-2027
Table 12.1 Pain Relieving Drugs: Market Forecast ($bn, CAGR%)
Table 12.2 Pain Relieving Drugs: Market Forecast ($bn) by Sector, 2016, 2021, 2027
Table 12.3 Global Pain Relieving Drugs: Market Shares (%) by Region, 2016, 2021, 2027

Companies Listed

AB Science
Abbott
AcelRx Pharmaceuticals
Actavis
Acura
Alder Biopharmaceuticals Inc
Alkem Laboratories Ltd.
Allergan
AlphaPharm
AlZA Corporation
Amgen
Apotex Corp.
Apotex Inc.
Arcion Therapeutics
Ascend Laboratories
AstraZeneca
Avanir Pharmaceuticals
Bayer
BioDelivery Sciences
Biogen Idec
Biovail Corporation
Boehringer Ingelheim
Boston Children Hospital
Bristol-Myers Squibb (BMS)
Centocor Ortho Biotech
China Aoxing
Chugai
Cilag GmbH
Cipla
CK Life Sciences
Collegium Pharmaceuticals
CoLucid Pharmaceuticals Inc
Dr Reddy’s
Durect
Eisai
Eli Lilly
Endo Pharmaceuticals
FDA
Forest
Genentech
Genmab
GlaxoSmithKline (GSK)
Grünenthal Group
Horizon Pharma
Human Genome Sciences
Immune Pharmaceuticals
Immunex
Impax Laboratories
Impax Pharmaceuticals
Insys Therapeutics
Ipsen
IVAX Pharmaceuticals
Janssen Pharmaceuticals
Johnson & Johnson
Kaiser Foundation Health Plan, Inc.
King Pharmaceuticals
Kyorin
Lexicon Pharmaceuticals
Lundbeck
Lupin Pharmaceuticals USA
McNeil Consumer Healthcare
Merck & Co.
Merck Serono
Mitsubishi Tanabe Pharma
Monsanto
Mundipharma
Mylan
NeurAxon
NeurogesX
Neurotune
Newron
NICE
NicOx
Novartis
Nupathe Inc.
Nuvo Research
Omeros
Ortho-McNeil, Inc.
Pacira Pharmaceuticals
Pain Therapeutics
Paion
Par Pharmaceuticals
Pfizer
Pfizer
PLx Pharma
Pozen Pharmaceutical
Proteus SA
Purdue Pharma
QRx Pharma
Roche
Roxane Laboratories
Samsung
Sandoz
Schering-Plough
Shionogi & Co Ltd.
Shire
Skyepharma
Spinifex Pharmaceuticals
Sun Pharmaceuticals
Syntaxin
Takeda
Teikoku
Teva
UCB
US Justice Department
US WorldMeds
Valeant Pharmaceuticals
Vapogenix Inc
Vitality Biopharma Inc.
Watson Pharmaceuticals
WEX Pharmaceuticals
WHO
Wyeth
Zars Pharmaceuticals
Zogenix

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close